All in: Boehringer Ingelheim more than doubles its venture fund to €250M
In a move that reflects the increasingly active role corporate VCs are playing in biotech, German pharma giant Boehringer Ingelheim is funneling an additional €150 million into its venture fund now totaling €250 million.
Along with the cash comes double the investment managers, and a second US-based office in 2018.
Frank Kalkbrenner, corporate VP and head of BIVF, said the new office will allow Boehringer to “collaborate more closely with biotech and startup companies on the West Coast.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
